Groups in terms of gestation rates and farrowing rates, litter results from birth to weaning or piglet index.

Further studies indicated that a lowered dose (37.5 μg) of peforelin 24 hours post weaning did not perform as well as the same amount.

In a preliminary study, it was determined that primiparous sows treated with 150 μg of peforelin achieved a farrowing rate of 93.9 %. The farrowing rate in peforelin treated animals was statistically better than untreated controls (p < 0.05), but not statistically better than the farrowing rate in animals treated with PMSG.

The di diferences between control and treated groups in terms of gestation rates and farrowing rates, litter results from birth to weaning or piglet index.

Cautions:

The safety of the product has not been established in sow and gilt during pregnancy and lactation.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.

Animal Safety:

An animal safety trial was performed in which doses of 1x and 3x the label dose were administered to sexually mature gilts. No adverse events were observed. The product was well tolerated by the animals and no reports of abnormal pathology related to the use of the product were observed. The safety of this product after repeat dosing has not been evaluated.

No withdrawal period is required for pigs when used according to the label.

The simultaneous use of the product with PMSG (Pregnant Mare Serum Gonadotropin) or hCG (Human chorionic gonadotropin) can possibly lead to an overreaction of the ovaries.